A Phase 3 interventional study of Alogliptin and Pioglitazone in Diabetes Mellitus, sponsored by Takeda. Completed at 161 sites in 23 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2013-03-27.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing alogliptin in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. alogliptin · Diabetes Mellitus, Type 2.
Among the 39 studies testing alogliptin in Diabetes Mellitus, Type 2, this one is the 8th largest by enrollment, is one of 8 that started in 2006, is one of 16 in phase 3, and was the 8th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →None of the 39 studies testing alogliptin in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →
alogliptin: first FDA approval 2013 (NESINA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 10 · Phase 3 23 · Phase 4 9
First in 2005; this study’s year is marked. 8 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 655 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 329 across the 39 interventional studies. Of the 35 that completed or were terminated, 30 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 39 have an industry lead sponsor. The 9 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
105 studies in Diabetes Mellitus, Type 2 by Takeda: none open now, none under way, none of them phase 3. Of 103 finished, 69 (67%) have results posted.
Among the 105 studies in Diabetes Mellitus, Type 2 by Takeda, this one is the 13th largest by enrollment of the 85 interventional ones that give a count, is one of 13 that started in 2006, is one of 45 in phase 3, and was the 14th registered.
Takeda’s Diabetes Mellitus, Type 2 studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 39 studies testing alogliptin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 105 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the combination of alogliptin, once daily (QD), and pioglitazone in patients with type 2 diabetes mellitus who are inadequately controlled with diet and exercise alone.
There are approximately 19 million people in the United States who have been diagnosed with diabetes mellitus, of which 90% to 95% is type 2. The prevalence of type 2 diabetes varies among racial and ethnic populations and has been shown to correlate with age, obesity, family history, history of gestational diabetes, and physical inactivity. Over the next decade, a marked increase in the number of adults with diabetes mellitus is expected, placing an ever-increasing burden on families and the health care system.
Current pharmacologic interventions for type 2 diabetes mellitus include a diverse range of antidiabetic medications with different mechanisms of action including insulin and insulin analogues, sulfonylureas, metformin, meglitinides, thiazolidinediones, inhibitors of alpha- glucosidase, analogs of glucagon-like peptide-1, and synthetic analogues of human amylin. Despite the variety of medications, many have clinically important or potentially life-threatening side effects, restricted use in many subpopulations, concerns with long-term tolerability, and challenges related to compliance due to side effects and route of administration. All of these reasons contribute to the difficulties patients have reaching the target glycosylated hemoglobin level less than 7%.
SYR-322 (alogliptin) is a selective, orally available inhibitor of the dipeptidyl peptidase-4 enzyme. Dipeptidyl peptidase-4 enzyme is thought to be primarily responsible for the in vivo degradation of 2 peptide hormones released in response to nutrient ingestion, namely glucagon-like peptide-1 and glucose-dependent insulinotropic peptide. Both peptides exert important effects on islet beta cells to stimulate glucose-dependent insulin secretion as well as regulating beta cell proliferation and cytoprotection. Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits gastric emptying, glucagon secretion, and food intake. Glucose-dependent insulinotropic peptide has been shown to enhance insulin secretion by direct interaction with a glucose-dependent insulinotropic peptide -specific receptor on islet beta cells. The glucose-lowering actions of glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, are preserved in patients with type 2 diabetes mellitus.
Pioglitazone (ACTOS®) is a thiazolidinedione developed by Takeda Chemical Industries, Ltd. (Osaka, Japan) that is approved for the treatment of type 2 diabetes mellitus. Pioglitazone is a selective peroxisome proliferator-activated receptor-gamma agonist that decreases insulin resistance in the periphery and liver resulting in increased insulin-dependent glucose disposal and decreased hepatic glucose output.
As the rate of newly diagnosed cases of type 2 diabetes mellitus continues to grow, so does the need for products that will provide better glycemic control and improved safety and tolerability. Alogliptin and pioglitazone have complementary actions. Alogliptin inhibits the degradation of glucagon-like peptide-1 by inhibiting the enzyme dipeptidyl peptidase IV, thus augmenting glucose-dependent insulin secretion while pioglitazone is a peripheral and hepatic insulin sensitizer. Given the complementary mechanisms of action of alogliptin (stimulates insulin secretion) and pioglitazone (enhances insulin sensitivity), the addition of combination therapy in treatment naïve type 2 diabetes patients may potentially allow the patients to reach and maintain their glycosylated hemoglobin goal more effectively.
The aim of this study is to evaluate the effectiveness of the combination of alogliptin with pioglitazone in patients who are inadequately controlled on diet and exercise alone. Study participation is anticipated to be approximately 8.5 months.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
This study's enrollment of 655 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.
Drug: Alogliptin · Drug: Placebo
Pioglitazone 30 mg, tablets, orally, once daily and alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.
Drug: Pioglitazone · Drug: Placebo
Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.
Drug: Alogliptin · Drug: Pioglitazone
Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.
Drug: Alogliptin · Drug: Pioglitazone
Alogliptin tablets.
Also known as: SYR-322
Pioglitazone tablets.
Also known as: Actos, AD4833
Matching placebo tablets.
Change From Baseline to Week 26 in Glycosylated Hemoglobin (HbA1c)
The change from Baseline to Week 26 in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound).
Time frame: Baseline and Week 26
Change From Baseline in HbA1c Over Time
The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) at 4 week intervals during the study. Least Squares Means were from an Analysis of Covariance (ANCOVA) model with treatment and geographic region as class variables and baseline HbA1c as a covariate.
Time frame: Baseline and Weeks 4, 8, 12, 16 and 20.
Change From Baseline in Fasting Plasma Glucose Over Time
The change from Baseline in fasting plasma glucose was assessed at weeks 1, 2, 4, 8, 12, 16, 20 and 26. Least Squares Means were from an ANCOVA model with treatment and geographic region as class variables and baseline plasma glucose as a covariate.
Time frame: Baseline and Weeks 1, 2, 4, 8, 12, 16, 20 and 26.
Percentage of Participants With Marked Hyperglycemia
Marked Hyperglycemia is defined as fasting plasma glucose greater than or equal to 200 mg/dL. Study week windows are defined to place hyperglycemia into visit categories.
Time frame: Weeks 1, 2, 4, 8, 12, 16, 20 and 26.
Percentage of Participants Meeting Rescue Criteria
Rescue was defined as meeting 1 of the following criteria, confirmed by a 2nd sample drawn within 5 days after the first sample and analyzed by the central laboratory: 1. After more than 4 weeks of treatment but prior to the Week 8 Visit: a single fasting plasma glucose ≥310 mg/dL (≥17.5 mmol/L); 2. From the Week 8 Visit but prior to the Week 12 Visit: a single fasting plasma glucose ≥275 mg/dL (≥15.27 mmol/L); 3. From the Week 12 Visit through the End-of-Treatment Visit: HbA1c ≥8.5% and ≤0.5% reduction in HbA1c as compared with the Baseline HbA1c.
Time frame: Weeks 4, 8, 12, 16, 20 and 26.
Percentage of Participants With Glycosylated Hemoglobin Less Than or Equal to 6.5%
Clinical response at Week 26 was assessed by the percentage of participants with HbA1c ≤6.5%.
Time frame: Week 26
Percentage of Participants With Glycosylated Hemoglobin Less Than or Equal to 7.0%
Clinical response at Week 26 was assessed by the percentage of participants with HbA1c ≤ 7%.
Time frame: Week 26
Percentage of Participants With Glycosylated Hemoglobin Less Than or Equal to 7.5%
Clinical response at Week 26 was assessed by the percentage of participants with HbA1c ≤ 7.5%.
Time frame: Week 26
Percentage of Participants With a Decrease in Glycosylated Hemoglobin Greater Than or Equal to 0.5%
Clinical response at Week 26 was assessed by the percentage of participants with a decrease from Baseline in HbA1c of ≥ 0.5%.
Time frame: Baseline and Week 26
Percentage of Participants With a Decrease in Glycosylated Hemoglobin Greater Than or Equal to 1.0%
Clinical response at Week 26 was assessed by the percentage of participants with a decrease from Baseline in HbA1c of ≥ 1%.
Time frame: Baseline and Week 26
Percentage of Participants With a Decrease in Glycosylated Hemoglobin Greater Than or Equal to 1.5%.
Clinical response at Week 26 was assessed by the percentage of participants with a decrease from Baseline in HbA1c of ≥ 1.5%.
Time frame: Baseline and Week 26
Percentage of Participants With a Decrease in Glycosylated Hemoglobin Greater Than or Equal to 2.0%
Clinical response at Week 26 was assessed by the percentage of participants with a decrease from Baseline in HbA1c of ≥ 2.0%.
Time frame: Baseline and Week 26
Change From Baseline in Fasting Proinsulin
Proinsulin is a precursor to insulin, and was measured as an indicator of pancreatic function. The change from Baseline in fasting proinsulin was assessed at Weeks 4, 8, 12, 16, 20 and 26. Least Squares Means were from an ANCOVA model with treatment and geographic region as class variables and baseline proinsulin as a covariate.
Time frame: Baseline and Weeks 4, 8, 12, 16, 20 and 26.
Change From Baseline in Insulin
The change from Baseline in fasting insulin was assessed at Weeks 4, 8, 12, 16, 20 and 26. Least Squares Means were from an ANCOVA model with treatment and geographic region as class variables and baseline insulin as a covariate.
Time frame: Baseline and Weeks 4, 8, 12, 16, 20 and 26.
Change From Baseline in Proinsulin/Insulin Ratio
The ratio of proinsulin to insulin was calculated as proinsulin (pmol/L) / insulin (μIU/mL) at weeks 4, 8, 12, 16, 20 and 26 relative to the Baseline value. Least squares means were from an ANCOVA model with treatment and geographic region as class variables and Baseline proinsulin/insulin ratio as a covariate.
Time frame: Baseline and Weeks 4, 8, 12, 16, 20 and 26.
Change From Baseline in C-peptide Levels
C-peptide is a byproduct created when the hormone insulin is produced and is measured by a blood test. Change from Baseline was assessed at Weeks 4, 8, 12, 16, 20 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline C-peptide as a covariate.
Time frame: Baseline and Weeks 4, 8, 12, 16, 20 and 26.
Change From Baseline in Calculated Homeostatic Model Assessment Insulin Resistance
The Homeostasis Model Assessment of insulin resistance (HOMA IR) measures insulin resistance based on fasting glucose and insulin measurements: HOMA IR = fasting plasma insulin (µIU/mL) \* fasting plasma glucose (mmol/L) / 22.5 A higher number indicates a greater degree of insulin resistance. The change from Baseline in HOMA IR was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline HOMA IR as a covariate.
Time frame: Baseline and Weeks 12 and 26.
Change From Baseline in Homeostatic Model Assessment Beta Cell Function
The Homeostasis Model Assessment (HOMA) estimates steady state beta cell function (%B) as a percentage of a normal reference population. HOMA %B = 20 \* insulin (µIU/mL) / fasting plasma glucose (mmol/L) - 3.5 The change from Baseline in the homeostasis model assessment of beta cell function was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline HOMA beta cell function as a covariate.
Time frame: Baseline and Weeks 12 and 26.
Change From Baseline in Body Weight
Change from Baseline in body weight was assessed at Weeks 8, 12, 20 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and Baseline weight as a covariate.
Time frame: Baseline and Weeks 8, 12, 20 and 26.
Change From Baseline in Total Cholesterol Level
Change from Baseline in total cholesterol level was assessed at Weeks 4, 8, 12, 16, 20 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline total cholesterol as a covariate.
Time frame: Baseline and Weeks 4, 8, 12, 16, 20 and 26.
Change From Baseline in Low-Density Lipoprotein Cholesterol
Change from Baseline in low-density lipoprotein cholesterol (LDL-C) was assessed at Weeks 4, 8, 12, 16, 20 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline LDL cholesterol as a covariate.
Time frame: Baseline and Weeks 4, 8, 12, 16, 20 and 26.
Change From Baseline in High-Density Lipoprotein Cholesterol
Change from Baseline in high-density lipoprotein cholesterol (HDL-C) was assessed at Weeks 4, 8, 12, 16, 20 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline HDL cholesterol as a covariate.
Time frame: Baseline and Weeks 4, 8, 12, 16, 20 and 26.
Change From Baseline in Triglyceride Levels
Change from Baseline in triglycerides was assessed at Weeks 4, 8, 12, 16, 20 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline triglycerides as a covariate.
Time frame: Baseline and Weeks 4, 8, 12, 16, 20 and 26.
Change From Baseline in Free Fatty Acids
Change from Baseline in free fatty acids (FFA) was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline free fatty acid as a covariate.
Time frame: Baseline and Weeks 12 and 26.
Change From Baseline in Plasminogen Activator Inhibitor-1
Change from Baseline in plasminogen activator inhibitor-1 was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline plasminogen activator inhibitor-1 as a covariate.
Time frame: Baseline and Weeks 12 and 26.
Change From Baseline in High-sensitivity C-Reactive Protein
Change from Baseline in high-sensitivity C-Reactive Protein (hsCRP) was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline hsCRP as a covariate.
Time frame: Baseline and Weeks 12 and 26.
Change From Baseline in Adiponectin
Change from Baseline in adiponectin was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline adiponectin as a covariate.
Time frame: Baseline and Weeks 12 and 26.
Change From Baseline in Apolipoprotein A1
Change from Baseline in Apolipoprotein A1 was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and Baseline apolipoprotein A1 as a covariate.
Time frame: Baseline and Weeks 12 and 26.
Change From Baseline in Apolipoprotein A2
Change from Baseline in apolipoprotein A2 was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline apolipoprotein A2 as a covariate.
Time frame: Baseline and Weeks 12 and 26.
Change From Baseline in Apolipoprotein B
Change from Baseline in apolipoprotein B was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline apolipoprotein B as a covariate.
Time frame: Baseline and Weeks 12 and 26.
Change From Baseline in Apolipoprotein C-III
Change from Baseline in apolipoprotein C-III was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline apolipoprotein C-III as a covariate.
Time frame: Baseline and Weeks 12 and 26.
Change From Baseline in Nuclear Magnetic Resonance Lipid Fractionation Total Triglycerides
Nuclear Magnetic Resonance (NMR) lipid fractionation was used to assess the change from Baseline in total triglyceride levels at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline NMR total triglycerides as a covariate.
Time frame: Baseline and Weeks 12 and 26.
Change From Baseline in Very Low Density Lipoprotein (VLDL) / Chylomicron Particles
The change from Baseline in levels of total VLDL/chylomicron particles and large VLDL/chylomicron particles was assessed by NMR lipid fractionation at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline VLDL/chylomicron particles as a covariate.
Time frame: Baseline and Weeks 12 and 26.
Change From Baseline in VLDL / Chylomicron Triglycerides
The change from Baseline in levels of VLDL/chylomicron triglycerides was assessed by NMR lipid fractionation at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline VLDL/chylomicron triglycerides as a covariate.
Time frame: Baseline and Weeks 12 and 26.
Change From Baseline in VLDL Particles
The change from Baseline in levels of medium VLDL particles and small VLDL particles was assessed by NMR fractionation at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline VLDL particles as a covariate.
Time frame: Baseline and Weeks 12 and 26.
Change From Baseline in Mean VLDL Particle Size
Change from Baseline in mean VLDL particle size was assessed by NMR lipid fractionation at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline mean VLDL particle size as a covariate.
Time frame: Baseline and Weeks 12 and 26.
Change From Baseline in Intermediate Density Lipoprotein (IDL) Particles
The change from Baseline in levels of IDL particles was assessed by NMR fractionation at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline IDL particles as a covariate.
Time frame: Baseline and Weeks 12 and 26.
Change From Baseline in Low Density Lipoprotein (LDL) Particles
The change from Baseline in levels of total, large, medium-small, total small and very small LDL particles was assessed by NMR fractionation at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline LDL particles as a covariate.
Time frame: Baseline and Weeks 12 and 26.
Change From Baseline in Mean LDL Particle Size
Change from Baseline in mean LDL particle size was assessed by NMR lipid fractionation at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline mean LDL particle size as a covariate.
Time frame: Baseline and Weeks 12 and 26.
Change From Baseline in High Density Lipoprotein (HDL) Particles
The change from Baseline in levels of total, large, medium and small HDL particles was assessed by NMR fractionation at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline HDL particles as a covariate.
Time frame: Baseline and Weeks 12 and 26.
Change From Baseline in Mean HDL Particle Size
Change from Baseline in mean HDL particle size was assessed by NMR lipid fractionation at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline mean HDL particle size as a covariate.
Time frame: Baseline and Weeks 12 and 26.
Participants took part in the study at 268 investigative sites in 23 countries from 02 November 2006 to 13 February 2008.
| Milestone | Alogliptin 25 mg | Pioglitazone 30 mg | Alogliptin 25 mg + Pioglitazone 30 mg | Alogliptin 12.5 mg + Pioglitazone 30 mg |
|---|---|---|---|---|
| Started | 164 | 163 | 164 | 164 |
| Safety set | 164 | 163 | 164 | 163 |
| Completed | 126 | 126 | 136 | 126 |
| Not completed | 38 | 37 | 28 | 38 |
| Withdrew: Adverse event | 3 | 8 | 6 | 6 |
| Withdrew: Protocol violation | 2 | 3 | 6 | 7 |
| Withdrew: Lost to follow-up | 2 | 6 | 5 | 5 |
| Withdrew: Withdrawal by subject | 6 | 5 | 5 | 12 |
| Withdrew: Physician decision | 6 | 4 | 2 | 2 |
| Withdrew: Other | 1 | 1 | 0 | 0 |
| Withdrew: Hyperglycemic rescue | 18 | 10 | 4 | 6 |
The change from Baseline to Week 26 in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound).
| percentage of glycosylated hemoglobin | Alogliptin 25 mg | Pioglitazone 30 mg | Alogliptin 25 mg + Pioglitazone 30 mg | Alogliptin 12.5 mg + Pioglitazone 30 mg |
|---|---|---|---|---|
| Change From Baseline to Week 26 in Glycosylated Hemoglobin (HbA1c) | -0.96 ± 0.081 | -1.15 ± 0.083 | -1.71 ± 0.081 | -1.56 ± 0.081 |
The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) at 4 week intervals during the study. Least Squares Means were from an Analysis of Covariance (ANCOVA) model with treatment and geographic region as class variables and baseline HbA1c as a covariate.
| percentage of glycosylated hemoglobin | Alogliptin 25 mg | Pioglitazone 30 mg | Alogliptin 25 mg + Pioglitazone 30 mg | Alogliptin 12.5 mg + Pioglitazone 30 mg |
|---|---|---|---|---|
| Week 4 (n=145, 146, 144, 150) | -0.55 ± 0.043 | -0.30 ± 0.043 | -0.62 ± 0.043 | -0.51 ± 0.043 |
| Week 8 (n=160, 153, 158, 158) | -0.84 ± 0.058 | -0.72 ± 0.060 | -1.19 ± 0.059 | -1.03 ± 0.059 |
| Week 12 (n=160, 153, 158, 158) | -0.98 ± 0.070 | -1.04 ± 0.071 | -1.57 ± 0.070 | -1.34 ± 0.070 |
| Week 16 (n=160, 153, 158, 158) | -1.01 ± 0.080 | -1.17 ± 0.082 | -1.67 ± 0.081 | -1.43 ± 0.081 |
| Week 20 (n=160, 153, 158, 158) | -1.00 ± 0.077 | -1.20 ± 0.079 | -1.72 ± 0.078 | -1.54 ± 0.078 |
The change from Baseline in fasting plasma glucose was assessed at weeks 1, 2, 4, 8, 12, 16, 20 and 26. Least Squares Means were from an ANCOVA model with treatment and geographic region as class variables and baseline plasma glucose as a covariate.
| mg/dL | Alogliptin 25 mg | Pioglitazone 30 mg | Alogliptin 25 mg + Pioglitazone 30 mg | Alogliptin 12.5 mg + Pioglitazone 30 mg |
|---|---|---|---|---|
| Week 1 (n=148, 146, 152, 151) | -14.6 ± 2.93 | -7.3 ± 2.95 | -26.6 ± 2.90 | -23.3 ± 2.91 |
| Week 2 (n=161, 156, 162, 159) | -16.7 ± 2.87 | -14.2 ± 2.92 | -33.5 ± 2.87 | -30.9 ± 2.90 |
| Week 4 (n=162, 157, 162, 161) | -26.7 ± 2.72 | -31.9 ± 2.76 | -41.4 ± 2.72 | -39.7 ± 2.73 |
| Week 8 (n=162, 157, 162, 162) | -29.0 ± 2.80 | -38.0 ± 2.84 | -50.4 ± 2.80 | -48.4 ± 2.81 |
| Week 12 (n=162, 157, 162, 162) | -29.5 ± 3.01 | -42.4 ± 3.05 | -51.9 ± 3.01 | -49.3 ± 3.01 |
| Week 16 (n=162, 157, 162, 162) | -26.9 ± 3.11 | -40.6 ± 3.16 | -52.7 ± 3.12 | -46.6 ± 3.12 |
| Week 20 (n=162, 157, 162, 162) | -28.3 ± 3.06 | -42.0 ± 3.11 | -54.0 ± 3.07 | -47.5 ± 3.07 |
| Week 26 (n=162, 157, 162, 162) | -25.8 ± 3.26 | -37.3 ± 3.31 | -50.2 ± 3.27 | -48.5 ± 3.27 |
Marked Hyperglycemia is defined as fasting plasma glucose greater than or equal to 200 mg/dL. Study week windows are defined to place hyperglycemia into visit categories.
| percentage of participants | Alogliptin 25 mg | Pioglitazone 30 mg | Alogliptin 25 mg + Pioglitazone 30 mg | Alogliptin 12.5 mg + Pioglitazone 30 mg |
|---|---|---|---|---|
| Week 1 to < Week 4 (n=162, 157, 162, 161) | 31.5 | 31.8 | 18.5 | 28.6 |
| Week 4 to < Week 8 (n=153, 147, 148, 147) | 19.0 | 15.0 | 10.8 | 14.3 |
| Week 8 to < Week 12 (n=151, 146, 152, 146) | 15.2 | 11.6 | 7.2 | 8.2 |
| Week 12 to < Week 16 (n=153, 141, 148, 139) | 16.3 | 9.2 | 8.1 | 7.9 |
| Week 16 to < Week 20 (n=142, 135, 144, 131) | 16.2 | 14.8 | 2.8 | 6.9 |
| Week 20 to Week 26 (n=130, 132, 143, 128) | 17.7 | 11.4 | 10.5 | 6.3 |
| Overall (n=162, 157, 162, 162) | 44.4 | 38.2 | 25.3 | 30.9 |
Rescue was defined as meeting 1 of the following criteria, confirmed by a 2nd sample drawn within 5 days after the first sample and analyzed by the central laboratory: 1. After more than 4 weeks of treatment but prior to the Week 8 Visit: a single fasting plasma glucose ≥310 mg/dL (≥17.5 mmol/L); 2. From the Week 8 Visit but prior to the Week 12 Visit: a single fasting plasma glucose ≥275 mg/dL (≥15.27 mmol/L); 3. From the Week 12 Visit through the End-of-Treatment Visit: HbA1c ≥8.5% and ≤0.5% reduction in HbA1c as compared with the Baseline HbA1c.
| percentage of participants | Alogliptin 25 mg | Pioglitazone 30 mg | Alogliptin 25 mg + Pioglitazone 30 mg | Alogliptin 12.5 mg + Pioglitazone 30 mg |
|---|---|---|---|---|
| Week 4 to < Week 8 (n=160, 156, 161, 160) | 0 | 0 | 0 | 0.6 |
| Week 8 to < Week 12 (n=158, 151, 157, 153) | 1.3 | 0 | 0 | 0 |
| Week 12 to < Week 16 (n=156, 145, 153, 144) | 2.6 | 3.4 | 1.3 | 2.1 |
| Week 16 to < Week 20 (n=150, 138, 149, 134) | 7.3 | 2.2 | 0 | 1.5 |
| Week 20 to Week 26 (n=132, 133, 146, 130) | 0.8 | 1.5 | 1.4 | 0 |
| Overall (n=160, 156, 161, 160) | 11.3 | 6.4 | 2.5 | 3.8 |
Clinical response at Week 26 was assessed by the percentage of participants with HbA1c ≤6.5%.
| percentage of participants | Alogliptin 25 mg | Pioglitazone 30 mg | Alogliptin 25 mg + Pioglitazone 30 mg | Alogliptin 12.5 mg + Pioglitazone 30 mg |
|---|---|---|---|---|
| Percentage of Participants With Glycosylated Hemoglobin Less Than or Equal to 6.5% | 11.6 | 16.6 | 27.4 | 26.4 |
Clinical response at Week 26 was assessed by the percentage of participants with HbA1c ≤ 7%.
| percentage of participants | Alogliptin 25 mg | Pioglitazone 30 mg | Alogliptin 25 mg + Pioglitazone 30 mg | Alogliptin 12.5 mg + Pioglitazone 30 mg |
|---|---|---|---|---|
| Percentage of Participants With Glycosylated Hemoglobin Less Than or Equal to 7.0% | 24.4 | 33.7 | 62.8 | 53.4 |
Clinical response at Week 26 was assessed by the percentage of participants with HbA1c ≤ 7.5%.
| percentage of participants | Alogliptin 25 mg | Pioglitazone 30 mg | Alogliptin 25 mg + Pioglitazone 30 mg | Alogliptin 12.5 mg + Pioglitazone 30 mg |
|---|---|---|---|---|
| Percentage of Participants With Glycosylated Hemoglobin Less Than or Equal to 7.5% | 44.5 | 55.8 | 72.0 | 72.4 |
Clinical response at Week 26 was assessed by the percentage of participants with a decrease from Baseline in HbA1c of ≥ 0.5%.
| percentage of participants | Alogliptin 25 mg | Pioglitazone 30 mg | Alogliptin 25 mg + Pioglitazone 30 mg | Alogliptin 12.5 mg + Pioglitazone 30 mg |
|---|---|---|---|---|
| Percentage of Participants With a Decrease in Glycosylated Hemoglobin Greater Than or Equal to 0.5% | 66.5 | 70.6 | 89.6 | 85.3 |
Clinical response at Week 26 was assessed by the percentage of participants with a decrease from Baseline in HbA1c of ≥ 1%.
| percentage of participants | Alogliptin 25 mg | Pioglitazone 30 mg | Alogliptin 25 mg + Pioglitazone 30 mg | Alogliptin 12.5 mg + Pioglitazone 30 mg |
|---|---|---|---|---|
| Percentage of Participants With a Decrease in Glycosylated Hemoglobin Greater Than or Equal to 1.0% | 43.3 | 54.6 | 75.6 | 68.1 |
Clinical response at Week 26 was assessed by the percentage of participants with a decrease from Baseline in HbA1c of ≥ 1.5%.
| percentage of participants | Alogliptin 25 mg | Pioglitazone 30 mg | Alogliptin 25 mg + Pioglitazone 30 mg | Alogliptin 12.5 mg + Pioglitazone 30 mg |
|---|---|---|---|---|
| Percentage of Participants With a Decrease in Glycosylated Hemoglobin Greater Than or Equal to 1.5%. | 29.3 | 33.1 | 57.3 | 50.9 |
Clinical response at Week 26 was assessed by the percentage of participants with a decrease from Baseline in HbA1c of ≥ 2.0%.
| percentage of participants | Alogliptin 25 mg | Pioglitazone 30 mg | Alogliptin 25 mg + Pioglitazone 30 mg | Alogliptin 12.5 mg + Pioglitazone 30 mg |
|---|---|---|---|---|
| Percentage of Participants With a Decrease in Glycosylated Hemoglobin Greater Than or Equal to 2.0% | 17.7 | 19.6 | 34.1 | 33.1 |
Proinsulin is a precursor to insulin, and was measured as an indicator of pancreatic function. The change from Baseline in fasting proinsulin was assessed at Weeks 4, 8, 12, 16, 20 and 26. Least Squares Means were from an ANCOVA model with treatment and geographic region as class variables and baseline proinsulin as a covariate.
| pmol/L | Alogliptin 25 mg | Pioglitazone 30 mg | Alogliptin 25 mg + Pioglitazone 30 mg | Alogliptin 12.5 mg + Pioglitazone 30 mg |
|---|---|---|---|---|
| Week 4 (n=136, 134, 135, 145) | -4.9 ± 1.74 | -12.1 ± 1.75 | -16.0 ± 1.74 | -12.3 ± 1.68 |
| Week 8 (n=150, 143, 146, 155) | -3.7 ± 1.57 | -14.9 ± 1.60 | -18.2 ± 1.59 | -17.7 ± 1.54 |
| Week 12 (n=150, 143, 147, 155) | -5.9 ± 1.48 | -16.0 ± 1.52 | -18.6 ± 1.50 | -16.7 ± 1.46 |
| Week 16 (n=150, 143, 147, 155) | -3.4 ± 1.88 | -16.3 ± 1.93 | -16.0 ± 1.90 | -13.1 ± 1.85 |
| Week 20 (n=150, 143, 147, 155) | -8.1 ± 1.75 | -16.1 ± 1.79 | -19.8 ± 1.76 | -15.5 ± 1.72 |
| Week 26 (n=150, 143, 147, 155) | -4.8 ± 1.64 | -13.2 ± 1.68 | -18.3 ± 1.66 | -15.1 ± 1.61 |
The change from Baseline in fasting insulin was assessed at Weeks 4, 8, 12, 16, 20 and 26. Least Squares Means were from an ANCOVA model with treatment and geographic region as class variables and baseline insulin as a covariate.
| μIU/mL | Alogliptin 25 mg | Pioglitazone 30 mg | Alogliptin 25 mg + Pioglitazone 30 mg | Alogliptin 12.5 mg + Pioglitazone 30 mg |
|---|---|---|---|---|
| Week 4 (n=135, 133, 133, 145) | 0.43 ± 0.684 | -4.74 ± 0.689 | -4.67 ± 0.687 | -4.27 ± 0.659 |
| Week 8 (n=150, 142, 147, 155) | 0.93 ± 0.811 | -4.41 ± 0.834 | -4.75 ± 0.818 | -4.86 ± 0.797 |
| Week 12 (n=150, 142, 148, 155) | 0.29 ± 0.883 | -4.08 ± 0.907 | -2.98 ± 0.887 | -4.65 ± 0.867 |
| Week 16 (n=150, 142, 148, 155) | 0.26 ± 0.829 | -4.49 ± 0.852 | -3.65 ± 0.833 | -2.73 ± 0.814 |
| Week 20 (n=150, 142, 148, 155) | -1.02 ± 0.844 | -4.56 ± 0.868 | -4.61 ± 0.848 | -3.06 ± 0.829 |
| Week 26 (n=150, 142, 148, 155) | -0.47 ± 0.755 | -4.06 ± 0.776 | -3.86 ± 0.759 | -3.72 ± 0.742 |
The ratio of proinsulin to insulin was calculated as proinsulin (pmol/L) / insulin (μIU/mL) at weeks 4, 8, 12, 16, 20 and 26 relative to the Baseline value. Least squares means were from an ANCOVA model with treatment and geographic region as class variables and Baseline proinsulin/insulin ratio as a covariate.
| ratio | Alogliptin 25 mg | Pioglitazone 30 mg | Alogliptin 25 mg + Pioglitazone 30 mg | Alogliptin 12.5 mg + Pioglitazone 30 mg |
|---|---|---|---|---|
| Week 4 (n=135, 133, 133, 145) | -0.073 ± 0.0150 | -0.047 ± 0.0151 | -0.080 ± 0.0151 | -0.056 ± 0.0144 |
| Week 8 (n=149, 142, 146, 155) | -0.041 ± 0.0140 | -0.085 ± 0.0144 | -0.094 ± 0.0142 | -0.102 ± 0.0138 |
| Week 12 (n=149, 142, 147, 155) | -0.062 ± 0.0122 | -0.098 ± 0.0125 | -0.123 ± 0.0123 | -0.095 ± 0.0120 |
| Week 16 (n=149, 142, 147, 155) | -0.049 ± 0.0173 | -0.081 ± 0.0177 | -0.115 ± 0.0174 | -0.090 ± 0.0170 |
| Week 20 (n=149, 142, 147, 155) | -0.057 ± 0.0173 | -0.076 ± 0.0177 | -0.124 ± 0.0174 | -0.119 ± 0.0169 |
| Week 26 (n=149, 142, 147, 155) | -0.051 ± 0.0145 | -0.076 ± 0.0148 | -0.107 ± 0.0146 | -0.102 ± 0.0142 |
C-peptide is a byproduct created when the hormone insulin is produced and is measured by a blood test. Change from Baseline was assessed at Weeks 4, 8, 12, 16, 20 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline C-peptide as a covariate.
| ng/mL | Alogliptin 25 mg | Pioglitazone 30 mg | Alogliptin 25 mg + Pioglitazone 30 mg | Alogliptin 12.5 mg + Pioglitazone 30 mg |
|---|---|---|---|---|
| Week 4 (n=142, 141, 141, 146) | 0.057 ± 0.0740 | -0.551 ± 0.0741 | -0.593 ± 0.0741 | -0.452 ± 0.0729 |
| Week 8 (n=158, 150, 153, 156) | 0.034 ± 0.0701 | -0.606 ± 0.0718 | -0.620 ± 0.0711 | -0.547 ± 0.0704 |
| Week 12 (n=158, 150, 154, 156) | -0.040 ± 0.0676 | -0.612 ± 0.0693 | -0.534 ± 0.0684 | -0.536 ± 0.0680 |
| Week 16 (n=158, 150, 154, 156) | 0.037 ± 0.0801 | -0.604 ± 0.0822 | -0.424 ± 0.0810 | -0.353 ± 0.0805 |
| Week 20 (n=158, 150, 154, 156) | -0.097 ± 0.0783 | -0.623 ± 0.0803 | -0.556 ± 0.0792 | -0.374 ± 0.0787 |
| Week 26 (n=158, 150, 154, 156) | -0.068 ± 0.0752 | -0.577 ± 0.0771 | -0.541 ± 0.0760 | -0.444 ± 0.0756 |
The Homeostasis Model Assessment of insulin resistance (HOMA IR) measures insulin resistance based on fasting glucose and insulin measurements: HOMA IR = fasting plasma insulin (µIU/mL) \* fasting plasma glucose (mmol/L) / 22.5 A higher number indicates a greater degree of insulin resistance. The change from Baseline in HOMA IR was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline HOMA IR as a covariate.
| insulin resistance | Alogliptin 25 mg | Pioglitazone 30 mg | Alogliptin 25 mg + Pioglitazone 30 mg | Alogliptin 12.5 mg + Pioglitazone 30 mg |
|---|---|---|---|---|
| Week 12 (n=139, 132, 137, 143) | -0.814 ± 0.5309 | -3.479 ± 0.5458 | -2.905 ± 0.5348 | -3.877 ± 0.5236 |
| Week 26 (n=145, 134, 144, 148) | -1.353 ± 0.3566 | -3.350 ± 0.3717 | -3.646 ± 0.3579 | -3.508 ± 0.3532 |
The Homeostasis Model Assessment (HOMA) estimates steady state beta cell function (%B) as a percentage of a normal reference population. HOMA %B = 20 \* insulin (µIU/mL) / fasting plasma glucose (mmol/L) - 3.5 The change from Baseline in the homeostasis model assessment of beta cell function was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline HOMA beta cell function as a covariate.
| percentage beta cell function | Alogliptin 25 mg | Pioglitazone 30 mg | Alogliptin 25 mg + Pioglitazone 30 mg | Alogliptin 12.5 mg + Pioglitazone 30 mg |
|---|---|---|---|---|
| Week 12 (n= 139, 132, 137, 143) | 15.133 ± 4.2787 | 17.328 ± 4.3868 | 30.266 ± 4.3006 | 22.134 ± 4.2098 |
| Week 26 (n=145, 134, 144, 148) | 10.472 ± 8.5306 | 17.500 ± 8.8718 | 39.153 ± 8.5455 | 24.887 ± 8.4285 |
Change from Baseline in body weight was assessed at Weeks 8, 12, 20 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and Baseline weight as a covariate.
| kg | Alogliptin 25 mg | Pioglitazone 30 mg | Alogliptin 25 mg + Pioglitazone 30 mg | Alogliptin 12.5 mg + Pioglitazone 30 mg |
|---|---|---|---|---|
| Week 8 (n=155, 146, 152, 151) | -0.34 ± 0.184 | 0.58 ± 0.189 | 0.82 ± 0.185 | 0.70 ± 0.186 |
| Week 12 (n=159, 147, 155, 154) | -0.78 ± 0.227 | 0.96 ± 0.236 | 1.35 ± 0.230 | 1.22 ± 0.230 |
| Week 20 (n=159, 147, 155, 154) | -0.47 ± 0.265 | 1.56 ± 0.275 | 2.36 ± 0.268 | 1.86 ± 0.269 |
| Week 26 (n=159, 147, 155, 154) | -0.29 ± 0.291 | 2.19 ± 0.302 | 3.14 ± 0.295 | 2.51 ± 0.296 |
Change from Baseline in total cholesterol level was assessed at Weeks 4, 8, 12, 16, 20 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline total cholesterol as a covariate.
| mg/dL | Alogliptin 25 mg | Pioglitazone 30 mg | Alogliptin 25 mg + Pioglitazone 30 mg | Alogliptin 12.5 mg + Pioglitazone 30 mg |
|---|---|---|---|---|
| Week 4 (n=146, 144, 142, 149) | -8.5 ± 2.22 | 0.9 ± 2.23 | -0.4 ± 2.25 | -5.3 ± 2.20 |
| Week 8 (n=160, 151, 154, 158) | -5.4 ± 2.30 | 7.2 ± 2.37 | -0.3 ± 2.34 | -1.2 ± 2.31 |
| Week 12 (n=160, 151, 155, 158) | -4.0 ± 2.43 | 4.9 ± 2.51 | -0.6 ± 2.47 | 4.4 ± 2.45 |
| Week 16 (n=160, 151, 155, 158) | -4.3 ± 2.42 | 4.6 ± 2.49 | 3.8 ± 2.46 | 4.7 ± 2.44 |
| Week 20 (n=160, 151, 155, 158) | -2.9 ± 2.67 | 4.5 ± 2.75 | -0.3 ± 2.71 | -0.6 ± 2.69 |
| Week 26 (n=160, 151, 155, 158) | -0.5 ± 2.61 | 6.5 ± 2.68 | 3.7 ± 2.65 | 4.0 ± 2.62 |
Change from Baseline in low-density lipoprotein cholesterol (LDL-C) was assessed at Weeks 4, 8, 12, 16, 20 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline LDL cholesterol as a covariate.
| mg/dL | Alogliptin 25 mg | Pioglitazone 30 mg | Alogliptin 25 mg + Pioglitazone 30 mg | Alogliptin 12.5 mg + Pioglitazone 30 mg |
|---|---|---|---|---|
| Week 4 (n=137, 130, 135, 142) | -3.5 ± 1.88 | 2.8 ± 1.93 | 2.2 ± 1.89 | -2.8 ± 1.85 |
| Week 8 (n=152, 139, 147, 153) | -0.5 ± 1.96 | 7.6 ± 2.05 | 2.6 ± 1.99 | 1.3 ± 1.95 |
| Week 12 (n=154, 140, 148, 154) | 0.8 ± 2.02 | 5.8 ± 2.12 | 1.4 ± 2.06 | 3.9 ± 2.02 |
| Week 16 (n=154, 140, 148, 154) | 1.8 ± 2.22 | 6.6 ± 2.33 | 5.3 ± 2.27 | 4.6 ± 2.22 |
| Week 20 (n=154, 140, 148, 154) | 0.9 ± 2.27 | 7.4 ± 2.38 | 2.1 ± 2.32 | 0.5 ± 2.27 |
| Week 26 (n=154, 140, 148, 154) | 2.0 ± 2.22 | 8.1 ± 2.33 | 4.6 ± 2.27 | 3.8 ± 2.22 |
Change from Baseline in high-density lipoprotein cholesterol (HDL-C) was assessed at Weeks 4, 8, 12, 16, 20 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline HDL cholesterol as a covariate.
| mg/dL | Alogliptin 25 mg | Pioglitazone 30 mg | Alogliptin 25 mg + Pioglitazone 30 mg | Alogliptin 12.5 mg + Pioglitazone 30 mg |
|---|---|---|---|---|
| Week 4 (n=146, 144, 142, 149) | -0.2 ± 0.54 | 3.0 ± 0.54 | 3.8 ± 0.55 | 3.0 ± 0.54 |
| Week 8 (n=160, 151, 154, 158) | 0.5 ± 0.56 | 4.7 ± 0.58 | 5.0 ± 0.57 | 4.8 ± 0.57 |
| Week 12 (n=160, 151, 155, 158) | 0.9 ± 0.64 | 6.0 ± 0.66 | 6.4 ± 0.65 | 6.5 ± 0.65 |
| Week 16 (n=160, 151, 155, 158) | 0.9 ± 0.57 | 5.2 ± 0.58 | 6.0 ± 0.58 | 5.9 ± 0.57 |
| Week 20 (n=160, 151, 155, 158) | 0.5 ± 0.59 | 4.7 ± 0.60 | 5.6 ± 0.60 | 5.6 ± 0.59 |
| Week 26 (n=160, 151, 155, 158) | 0.8 ± 0.64 | 5.7 ± 0.66 | 6.2 ± 0.65 | 6.2 ± 0.64 |
Change from Baseline in triglycerides was assessed at Weeks 4, 8, 12, 16, 20 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline triglycerides as a covariate.
| mg/dL | Alogliptin 25 mg | Pioglitazone 30 mg | Alogliptin 25 mg + Pioglitazone 30 mg | Alogliptin 12.5 mg + Pioglitazone 30 mg |
|---|---|---|---|---|
| Week 4 (n=146, 144, 142, 149) | -28.2 ± 8.60 | -43.2 ± 8.63 | -51.7 ± 8.70 | -32.1 ± 8.51 |
| Week 8 (n=160, 151, 154, 158) | -34.8 ± 6.51 | -38.2 ± 6.69 | -61.6 ± 6.63 | -51.9 ± 6.56 |
| Week 12 (n=160, 151, 155, 158) | -36.4 ± 6.90 | -47.9 ± 7.09 | -64.3 ± 7.00 | -45.4 ± 6.95 |
| Week 16 (n=160, 151, 155, 158) | -44.5 ± 5.74 | -48.3 ± 5.90 | -54.6 ± 5.82 | -43.9 ± 5.78 |
| Week 20 (n=160, 151, 155, 158) | -29.9 ± 7.35 | -46.6 ± 7.56 | -59.3 ± 7.46 | -46.5 ± 7.41 |
| Week 26 (n=160, 151, 155, 158) | -24.7 ± 6.83 | -46.6 ± 7.02 | -56.2 ± 6.92 | -43.1 ± 6.88 |
Change from Baseline in free fatty acids (FFA) was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline free fatty acid as a covariate.
| mmol/L | Alogliptin 25 mg | Pioglitazone 30 mg | Alogliptin 25 mg + Pioglitazone 30 mg | Alogliptin 12.5 mg + Pioglitazone 30 mg |
|---|---|---|---|---|
| Week 12 (n=148, 136, 140, 147) | -0.0404 ± 0.01643 | -0.0990 ± 0.01716 | -0.1061 ± 0.01690 | -0.0805 ± 0.01650 |
| Week 26 (n=154, 136, 147, 150) | -0.0429 ± 0.01624 | -0.0680 ± 0.01729 | -0.0881 ± 0.01662 | -0.1013 ± 0.01647 |
Change from Baseline in plasminogen activator inhibitor-1 was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline plasminogen activator inhibitor-1 as a covariate.
| ng/mL | Alogliptin 25 mg | Pioglitazone 30 mg | Alogliptin 25 mg + Pioglitazone 30 mg | Alogliptin 12.5 mg + Pioglitazone 30 mg |
|---|---|---|---|---|
| Week 12 (n=136, 127, 131, 133) | -1.58 ± 2.815 | -4.23 ± 2.909 | -9.63 ± 2.870 | -11.87 ± 2.849 |
| Week 26 (n=145, 129, 142, 137) | 1.71 ± 3.151 | -5.45 ± 3.341 | -7.14 ± 3.189 | -8.38 ± 3.246 |
Change from Baseline in high-sensitivity C-Reactive Protein (hsCRP) was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline hsCRP as a covariate.
| mg/L | Alogliptin 25 mg | Pioglitazone 30 mg | Alogliptin 25 mg + Pioglitazone 30 mg | Alogliptin 12.5 mg + Pioglitazone 30 mg |
|---|---|---|---|---|
| Week 12 (n=147, 134, 138, 146) | -0.4497 ± 0.41497 | -1.7446 ± 0.43493 | -1.5346 ± 0.42831 | -2.2771 ± 0.41646 |
| Week 26 (n=153, 135, 144, 149) | -0.1851 ± 0.42623 | -1.0391 ± 0.45388 | -1.9763 ± 0.43925 | -1.9796 ± 0.43182 |
Change from Baseline in adiponectin was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline adiponectin as a covariate.
| μg/mL | Alogliptin 25 mg | Pioglitazone 30 mg | Alogliptin 25 mg + Pioglitazone 30 mg | Alogliptin 12.5 mg + Pioglitazone 30 mg |
|---|---|---|---|---|
| Week 12 (n=148, 137, 141, 147) | -0.28 ± 0.560 | 6.35 ± 0.582 | 8.10 ± 0.575 | 7.50 ± 0.562 |
| Week 26 (n=154, 137, 147, 149) | -0.09 ± 0.570 | 6.90 ± 0.605 | 6.85 ± 0.586 | 7.16 ± 0.581 |
Change from Baseline in Apolipoprotein A1 was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and Baseline apolipoprotein A1 as a covariate.
| mg/dL | Alogliptin 25 mg | Pioglitazone 30 mg | Alogliptin 25 mg + Pioglitazone 30 mg | Alogliptin 12.5 mg + Pioglitazone 30 mg |
|---|---|---|---|---|
| Week 12 (n=140, 138, 137, 144) | -1.6 ± 1.57 | 2.3 ± 1.58 | 1.0 ± 1.59 | 1.7 ± 1.55 |
| Week 26 (n=149, 139, 146, 146) | -4.5 ± 1.59 | 1.2 ± 1.64 | 0.8 ± 1.60 | 1.6 ± 1.60 |
Change from Baseline in apolipoprotein A2 was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline apolipoprotein A2 as a covariate.
| mg/dL | Alogliptin 25 mg | Pioglitazone 30 mg | Alogliptin 25 mg + Pioglitazone 30 mg | Alogliptin 12.5 mg + Pioglitazone 30 mg |
|---|---|---|---|---|
| Week 12 (n=140, 138, 137, 144) | -0.1 ± 0.41 | 3.4 ± 0.41 | 2.8 ± 0.41 | 3.2 ± 0.40 |
| Week 26 (n=149, 139, 146, 146) | -0.3 ± 0.41 | 2.9 ± 0.43 | 2.5 ± 0.42 | 2.6 ± 0.42 |
Change from Baseline in apolipoprotein B was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline apolipoprotein B as a covariate.
| mg/dL | Alogliptin 25 mg | Pioglitazone 30 mg | Alogliptin 25 mg + Pioglitazone 30 mg | Alogliptin 12.5 mg + Pioglitazone 30 mg |
|---|---|---|---|---|
| Week 12 (n=140, 138, 137, 143) | -4.0 ± 1.76 | -5.0 ± 1.78 | -9.8 ± 1.78 | -5.9 ± 1.74 |
| Week 26 (n=149, 139, 146, 146) | -2.5 ± 1.84 | -3.7 ± 1.91 | -7.9 ± 1.86 | -6.4 ± 1.86 |
Change from Baseline in apolipoprotein C-III was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline apolipoprotein C-III as a covariate.
| mg/dL | Alogliptin 25 mg | Pioglitazone 30 mg | Alogliptin 25 mg + Pioglitazone 30 mg | Alogliptin 12.5 mg + Pioglitazone 30 mg |
|---|---|---|---|---|
| Week 12 (n=140, 138, 138, 144) | -0.5 ± 0.30 | -0.3 ± 0.30 | -0.8 ± 0.30 | -0.3 ± 0.30 |
| Week 26 (n=149, 139, 147, 146) | -0.4 ± 0.28 | -0.2 ± 0.29 | -0.3 ± 0.28 | -0.4 ± 0.28 |
Nuclear Magnetic Resonance (NMR) lipid fractionation was used to assess the change from Baseline in total triglyceride levels at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline NMR total triglycerides as a covariate.
| mg/dL | Alogliptin 25 mg | Pioglitazone 30 mg | Alogliptin 25 mg + Pioglitazone 30 mg | Alogliptin 12.5 mg + Pioglitazone 30 mg |
|---|---|---|---|---|
| Week 12 (n=139, 132, 132, 141) | -14.9 ± 6.36 | -25.0 ± 6.52 | -39.7 ± 6.52 | -23.7 ± 6.32 |
| Week 26 (n=147, 133, 141, 147) | -7.6 ± 5.82 | -20.2 ± 6.11 | -28.8 ± 5.94 | -22.6 ± 5.82 |
The change from Baseline in levels of total VLDL/chylomicron particles and large VLDL/chylomicron particles was assessed by NMR lipid fractionation at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline VLDL/chylomicron particles as a covariate.
| nmol/L | Alogliptin 25 mg | Pioglitazone 30 mg | Alogliptin 25 mg + Pioglitazone 30 mg | Alogliptin 12.5 mg + Pioglitazone 30 mg |
|---|---|---|---|---|
| Total Particles - Week 12 (n=139, 132, 132, 141) | -6.59 ± 2.600 | 0.70 ± 2.663 | -9.63 ± 2.664 | -2.67 ± 2.578 |
| Total Particles - Week 26 (n=147, 133, 141, 147) | -4.97 ± 2.831 | 4.94 ± 2.976 | -0.73 ± 2.888 | -1.17 ± 2.828 |
| Large Particles - Week 12 (n=139, 132, 132, 141) | -0.94 ± 0.511 | -1.83 ± 0.525 | -2.63 ± 0.525 | -2.06 ± 0.508 |
| Large Particles - Week 26 (n=147, 133, 141, 147) | -0.18 ± 0.480 | -1.96 ± 0.505 | -2.37 ± 0.490 | -2.11 ± 0.480 |
The change from Baseline in levels of VLDL/chylomicron triglycerides was assessed by NMR lipid fractionation at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline VLDL/chylomicron triglycerides as a covariate.
| mg/dL | Alogliptin 25 mg | Pioglitazone 30 mg | Alogliptin 25 mg + Pioglitazone 30 mg | Alogliptin 12.5 mg + Pioglitazone 30 mg |
|---|---|---|---|---|
| Week 12 (n=139, 132, 132, 141) | -14.4 ± 6.34 | -25.6 ± 6.50 | -39.5 ± 6.50 | -24.2 ± 6.30 |
| Week 26 (n=147, 133, 141, 147) | -8.2 ± 5.79 | -22.0 ± 6.08 | -29.7 ± 5.90 | -23.3 ± 5.79 |
The change from Baseline in levels of medium VLDL particles and small VLDL particles was assessed by NMR fractionation at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline VLDL particles as a covariate.
| nmol/L | Alogliptin 25 mg | Pioglitazone 30 mg | Alogliptin 25 mg + Pioglitazone 30 mg | Alogliptin 12.5 mg + Pioglitazone 30 mg |
|---|---|---|---|---|
| Medium Particles - Week 12 (n=139, 132, 132, 141) | -3.20 ± 1.639 | -2.30 ± 1.678 | -8.52 ± 1.679 | -4.69 ± 1.625 |
| Medium Particles - Week 26 (n=147, 133, 141, 147) | -0.23 ± 1.784 | -0.39 ± 1.874 | -3.76 ± 1.819 | -3.58 ± 1.782 |
| Small Particles - Week 12 (n=139, 132, 132, 141) | -1.74 ± 1.617 | 4.77 ± 1.662 | 1.18 ± 1.660 | 3.71 ± 1.607 |
| Small Particles - Week 26 (n=147, 133, 141, 147) | -4.11 ± 1.710 | 7.16 ± 1.802 | 5.22 ± 1.746 | 4.36 ± 1.711 |
Change from Baseline in mean VLDL particle size was assessed by NMR lipid fractionation at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline mean VLDL particle size as a covariate.
| nm | Alogliptin 25 mg | Pioglitazone 30 mg | Alogliptin 25 mg + Pioglitazone 30 mg | Alogliptin 12.5 mg + Pioglitazone 30 mg |
|---|---|---|---|---|
| Week 12 (n=139, 132, 132, 141) | -0.97 ± 0.668 | -3.97 ± 0.688 | -2.92 ± 0.687 | -2.85 ± 0.665 |
| Week 26 (n=147, 133, 141, 147) | 0.30 ± 0.607 | -3.71 ± 0.640 | -4.21 ± 0.620 | -2.80 ± 0.607 |
The change from Baseline in levels of IDL particles was assessed by NMR fractionation at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline IDL particles as a covariate.
| nmol/L | Alogliptin 25 mg | Pioglitazone 30 mg | Alogliptin 25 mg + Pioglitazone 30 mg | Alogliptin 12.5 mg + Pioglitazone 30 mg |
|---|---|---|---|---|
| Week 12 (n=139, 132, 132, 141) | -2.9 ± 3.63 | -1.0 ± 3.72 | -2.9 ± 3.73 | -4.0 ± 3.61 |
| Week 26 (n=147, 133, 141, 147) | 0.5 ± 3.68 | 2.1 ± 3.86 | -1.0 ± 3.75 | -5.8 ± 3.68 |
The change from Baseline in levels of total, large, medium-small, total small and very small LDL particles was assessed by NMR fractionation at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline LDL particles as a covariate.
| nmol/L | Alogliptin 25 mg | Pioglitazone 30 mg | Alogliptin 25 mg + Pioglitazone 30 mg | Alogliptin 12.5 mg + Pioglitazone 30 mg |
|---|---|---|---|---|
| Total Particles - Week 12 (n=139, 132, 132, 141) | -11.9 ± 28.57 | -104.1 ± 29.34 | -207.0 ± 29.33 | -181.8 ± 28.40 |
| Total Particles - Week 26 (n=147, 133, 141, 147) | 60.9 ± 30.67 | -75.6 ± 32.29 | -169.9 ± 31.31 | -177.1 ± 30.68 |
| Large Particles - Week 12 (n=139, 132, 132, 141) | 15.3 ± 15.16 | 98.8 ± 15.52 | 129.4 ± 15.54 | 142.1 ± 15.05 |
| Large Particles - Week 26 (n=147, 133, 141, 147) | 2.6 ± 15.32 | 120.4 ± 16.10 | 146.6 ± 15.63 | 155.5 ± 15.33 |
| Medium-Small - Week 12 (n=139, 132, 132, 141) | -6.2 ± 6.25 | -41.4 ± 6.41 | -65.8 ± 6.41 | -65.8 ± 6.20 |
| Medium-Small - Week 26 (n=147, 133, 141, 147) | 9.9 ± 6.42 | -40.1 ± 6.75 | -63.0 ± 6.55 | -66.6 ± 6.41 |
| Total Small - Week 12 (n=139, 132, 132, 141) | -27.8 ± 31.91 | -200.3 ± 32.71 | -331.2 ± 32.73 | -320.0 ± 31.66 |
| Total Small - Week 26 (n=147, 133, 141, 147) | 54.5 ± 33.34 | -195.8 ± 35.04 | -313.8 ± 34.01 | -327.4 ± 33.30 |
| Very Small - Week 12 (n=139, 132, 132, 141) | -20.9 ± 26.22 | -159.2 ± 26.88 | -265.7 ± 26.90 | -254.2 ± 26.02 |
| Very Small - Week 26 (n=147, 133, 141, 147) | 45.1 ± 27.44 | -156.0 ± 28.83 | -250.9 ± 27.98 | -260.8 ± 27.40 |
Change from Baseline in mean LDL particle size was assessed by NMR lipid fractionation at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline mean LDL particle size as a covariate.
| nm | Alogliptin 25 mg | Pioglitazone 30 mg | Alogliptin 25 mg + Pioglitazone 30 mg | Alogliptin 12.5 mg + Pioglitazone 30 mg |
|---|---|---|---|---|
| Week 12 (n=139, 132, 132, 141) | 0.09 ± 0.051 | 0.44 ± 0.053 | 0.63 ± 0.053 | 0.58 ± 0.051 |
| Week 26 (n=147, 133, 141, 147) | -0.02 ± 0.052 | 0.44 ± 0.054 | 0.65 ± 0.053 | 0.61 ± 0.052 |
The change from Baseline in levels of total, large, medium and small HDL particles was assessed by NMR fractionation at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline HDL particles as a covariate.
| µmol/L | Alogliptin 25 mg | Pioglitazone 30 mg | Alogliptin 25 mg + Pioglitazone 30 mg | Alogliptin 12.5 mg + Pioglitazone 30 mg |
|---|---|---|---|---|
| Total Particles - Week 12 (n=139, 132, 132, 141) | 0.18 ± 0.350 | 0.92 ± 0.359 | 0.11 ± 0.359 | 0.54 ± 0.348 |
| Total Particles - Week 26 (n=147, 133, 141, 147) | 0.81 ± 0.359 | 1.67 ± 0.377 | 1.01 ± 0.367 | 1.03 ± 0.359 |
| Large Particles - Week 12 (n=139, 132, 132, 141) | 0.07 ± 0.195 | 0.99 ± 0.200 | 0.98 ± 0.200 | 1.31 ± 0.193 |
| Large Particles - Week 26 (n=147, 133, 141, 147) | -0.06 ± 0.197 | 1.14 ± 0.207 | 1.24 ± 0.201 | 1.31 ± 0.197 |
| Medium Particles - Week 12 (n=139, 132, 132, 141) | -0.26 ± 0.311 | 0.72 ± 0.319 | 1.60 ± 0.320 | 1.61 ± 0.308 |
| Medium Particles - Week 26 (n=147, 133, 141, 147) | -0.26 ± 0.313 | 0.95 ± 0.329 | 1.19 ± 0.320 | 1.30 ± 0.312 |
| Small Particles - Week 12 (n=139, 132, 132, 141) | 0.50 ± 0.412 | -0.68 ± 0.423 | -2.65 ± 0.423 | -2.42 ± 0.410 |
| Small Particles - Week 26 (n=147, 133, 141, 147) | 1.24 ± 0.412 | -0.28 ± 0.433 | -1.58 ± 0.421 | -1.63 ± 0.413 |
Change from Baseline in mean HDL particle size was assessed by NMR lipid fractionation at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline mean HDL particle size as a covariate.
| nm | Alogliptin 25 mg | Pioglitazone 30 mg | Alogliptin 25 mg + Pioglitazone 30 mg | Alogliptin 12.5 mg + Pioglitazone 30 mg |
|---|---|---|---|---|
| Week 12 (n=139, 132, 132, 141) | -0.02 ± 0.024 | 0.09 ± 0.025 | 0.17 ± 0.025 | 0.15 ± 0.024 |
| Week 26 (n=147, 133, 141, 147) | -0.03 ± 0.024 | 0.08 ± 0.025 | 0.15 ± 0.024 | 0.14 ± 0.024 |
Collected over Adverse events were collected from the time of informed consent until the end of the study, and from spontaneous reporting for 30 days after the end of treatment.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Alogliptin 25 mg | — | 1/164 (0.6%) | 19/164 (11.6%) |
| Pioglitazone 30 mg | — | 6/163 (3.7%) | 25/163 (15.3%) |
| Alogliptin 25 mg + Pioglitazone 30 mg | — | 8/164 (4.9%) | 37/164 (22.6%) |
| Alogliptin 12.5 mg + Pioglitazone 30 mg | — | 1/163 (0.6%) | 24/163 (14.7%) |
| Event | Alogliptin 25 mg | Pioglitazone 30 mg | Alogliptin 25 mg + Pioglitazone 30 mg | Alogliptin 12.5 mg + Pioglitazone 30 mg |
|---|---|---|---|---|
| Non-cardiac chest painGeneral disorders | 0/164 | 1/163 | 0/164 | 0/163 |
| HypertriglyceridaemiaMetabolism and nutrition disorders | 0/164 | 1/163 | 0/164 | 0/163 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 0/164 | 1/163 | 0/164 | 0/163 |
| Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/164 | 1/163 | 0/164 | 0/163 |
| SyncopeNervous system disorders | 0/164 | 1/163 | 1/164 | 0/163 |
| Cerebral ischaemiaNervous system disorders | 0/164 | 1/163 | 0/164 | 0/163 |
| EndometriosisReproductive system and breast disorders | 0/164 | 0/163 | 0/164 | 1/163 |
| Acute myocardial infarctionCardiac disorders | 0/164 | 0/163 | 1/164 | 0/163 |
| Angina unstableCardiac disorders | 1/164 | 0/163 | 0/164 | 0/163 |
| Retinal detachmentEye disorders | 0/164 | 0/163 | 1/164 | 0/163 |
| Event | Alogliptin 25 mg | Pioglitazone 30 mg | Alogliptin 25 mg + Pioglitazone 30 mg | Alogliptin 12.5 mg + Pioglitazone 30 mg |
|---|---|---|---|---|
| HeadacheNervous system disorders | 11/164 | 11/163 | 20/164 | 14/163 |
| Back painMusculoskeletal and connective tissue disorders | 1/164 | 3/163 | 10/164 | 3/163 |
| Oedema peripheralGeneral disorders | 2/164 | 9/163 | 4/164 | 2/163 |
| Urinary tract infectionInfections and infestations | 5/164 | 4/163 | 9/164 | 6/163 |
| Age Continuous(years) | Alogliptin 25 mg | Pioglitazone 30 mg | Alogliptin 25 mg + Pioglitazone 30 mg | Alogliptin 12.5 mg + Pioglitazone 30 mg | Total |
|---|---|---|---|---|---|
| Mean | 52.6 ± 10.38 | 51.5 ± 10.72 | 52.8 ± 11.01 | 53.5 ± 11.37 | 52.6 ± 10.88 |
| Age, Customized(participants) | Alogliptin 25 mg | Pioglitazone 30 mg | Alogliptin 25 mg + Pioglitazone 30 mg | Alogliptin 12.5 mg + Pioglitazone 30 mg | Total |
|---|---|---|---|---|---|
| < 65 years | 144 | 143 | 140 | 130 | 557 |
| ≥ 65 years | 20 | 20 | 24 | 34 | 98 |
| Sex: Female, Male(Participants) | Alogliptin 25 mg | Pioglitazone 30 mg | Alogliptin 25 mg + Pioglitazone 30 mg | Alogliptin 12.5 mg + Pioglitazone 30 mg | Total |
|---|---|---|---|---|---|
| Female | 88 | 73 | 91 | 83 | 335 |
| Male | 76 | 90 | 73 | 81 | 320 |
| Ethnicity (NIH/OMB)(Participants) | Alogliptin 25 mg | Pioglitazone 30 mg | Alogliptin 25 mg + Pioglitazone 30 mg | Alogliptin 12.5 mg + Pioglitazone 30 mg | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 63 | 65 | 58 | 62 | 248 |
| Not Hispanic or Latino | 101 | 98 | 106 | 102 | 407 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Alogliptin 25 mg | Pioglitazone 30 mg | Alogliptin 25 mg + Pioglitazone 30 mg | Alogliptin 12.5 mg + Pioglitazone 30 mg | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 0 | 1 |
| Asian | 14 | 15 | 12 | 16 | 57 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 1 | 1 |
| Black or African American | 8 | 9 | 12 | 9 | 38 |
| White | 135 | 130 | 129 | 132 | 526 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 6 | 9 | 11 | 6 | 32 |
| Weight(kg) | Alogliptin 25 mg | Pioglitazone 30 mg | Alogliptin 25 mg + Pioglitazone 30 mg | Alogliptin 12.5 mg + Pioglitazone 30 mg | Total |
|---|---|---|---|---|---|
| Mean | 86.72 ± 19.033 | 85.53 ± 16.254 | 85.39 ± 20.374 | 84.38 ± 20.378 | 85.50 ± 19.062 |
| Body Mass Index (BMI)(kg/m^2) | Alogliptin 25 mg | Pioglitazone 30 mg | Alogliptin 25 mg + Pioglitazone 30 mg | Alogliptin 12.5 mg + Pioglitazone 30 mg | Total |
|---|---|---|---|---|---|
| Mean | 31.61 ± 5.587 | 30.87 ± 4.938 | 31.32 ± 5.354 | 30.71 ± 5.621 | 31.13 ± 5.382 |
| Duration of diabetes(years) | Alogliptin 25 mg | Pioglitazone 30 mg | Alogliptin 25 mg + Pioglitazone 30 mg | Alogliptin 12.5 mg + Pioglitazone 30 mg | Total |
|---|---|---|---|---|---|
| Mean | 3.23 ± 3.559 | 3.20 ± 3.739 | 3.05 ± 3.328 | 3.36 ± 4.166 | 3.21 ± 3.704 |
Showing the first 100 of 161 sites across 23 countries. Choose a country and city above to see the rest.
The record gives a start of Nov 2006, a primary completion of Feb 2008 and a completion of Feb 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2013, 5 years 1 month after primary completion. A results delay was requested in Jul 2009.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Alogliptin · Pioglitazone